Phibro Animal Health

PAHC

Market cap $1.37B

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Lonza Group Ag (LZAGY). But which of these two stocks is more attractive to value investors?

Investors need to pay close attention to PAHC stock based on the movements in the options market lately.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Phibro (PAHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?

Phibro (PAHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Phibro Animal Health gains from Animal Health strength and Zoetis MFA integration, but macro and FX headwinds remain as the stock rises 27.6% over the past year.

Corcoran purchased 10,000 shares for a transaction value of approximately ~$318,000 on May 29, 2026. The buy increased his direct ownership by 31.79%, bringing his post-transaction direct holdings to 41,459 shares.

Phibro Animal Health unit drove 74% of fiscal 2025 revenue, fueled by MFA, vaccines and global expansion, helping offset pressure in other businesses.